Reportlinker Adds Multiplex Assays: Evolving Technologies, Applications and Future Directions

Jan 04, 2010, 09:29 ET from Reportlinker

NEW YORK, Jan. 4 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Multiplex Assays: Evolving Technologies, Applications and Future Directions

http://www.reportlinker.com/p0170672/Multiplex-Assays-Evolving-Technologies-Applications-and-Future-Directions.html

The human immune system can go awry, either attacking an individual's body or producing an exaggerated response to a foreign substance that is normally benign. In these situations, immunotherapies are needed to balance or suppress the unwarranted immune response.

In this report:

Approximately 400 product candidates and development programs are identified. Current and emerging therapies for selected autoimmune or inflammatory disorders and prevention of organ transplant rejection, directed against a wide range of putative targets, are summarized.

Specifically, more than 250 emerging autoimmune disease therapies, 80 asthma therapies in development, and 50+ therapy candidates for allergies are covered. The strategic consequences of intense competition in a crowded product space are considered.

Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response reviews the problems of insufficient efficacy, side effects, and adverse events associated with the small-molecule and biological drugs available today to treat these disorders. These observations have led to an interest in identifying ways to balance the immune reaction, to suppress the part of the immune response that is causing the disease, while maintaining or enhancing other aspects of the immune system. This report identifies nearly 400 ongoing product candidates and development programs in these indication areas. The companies active in these areas range from multinational pharmaceutical companies with a number of active programs to small boutique start-ups working on a very defined topic.

CHAPTER 1: INTRODUCTION

1.1. The Immune System

1.2. Scope of the Report

CHAPTER 2: REVIEW OF MAJOR DISEASES/ CONDITIONS TARGETED BY NEW AND/OR EMERGING IMMUNOTHERAPIES AND VACCINES TO SUPPRESS OR BALANCE THE IMMUNE SYSTEM

2.1. Major Autoimmune Diseases

Rheumatoid Arthritis

Type 1 Diabetes Mellitus

Inflammatory Bowel Disease--Crohn's

Disease and Ulcerative Colitis

Multiple Sclerosis

Psoriasis

Psoriatic Arthritis

Systemic Lupus Erythematosus

2.2. Asthma

2.3. Allergies

2.4. Immune Suppression to Prevent

Rejection of Organ Transplants

CHAPTER 3: CURRENT PHARMACOLOGICAL TREATMENT OPTIONS

3.1. Major Autoimmune Diseases

Rheumatoid Arthritis

Nonsteroidal Anti-inflammatory Drugs

(NSAIDs)

Disease-Modifying Antirheumatic

Drugs (DMARDs)

Corticosteroids

Biological Response Modifiers

Type 1 Diabetes Mellitus

Inflammatory Bowel Disease--Crohn's

Disease and Ulcerative Colitis

Multiple Sclerosis

Interferon-beta

Copaxone (glatiramer acetate)

Novantrone (mitoxantrone)

Tysabri (natalizumab)

Psoriasis

Psoriatic Arthritis

Systemic Lupus Erythematosus

3.2. Asthma

3.3. Allergies

3.4. Immune Suppression to Prevent Rejection of Organ Transplants

CHAPTER 4: CURRENT AND EMERGING APPROACHES TO SUPPRESS OR BALANCE THE IMMUNE SYSTEM FOR PREVENTION AND TREATMENT OF DISEASE

CHAPTER 5: EMERGING THERAPIES IN DEVELOPMENT FOR TREATMENT OF MAJOR AUTOIMMUNE DISEASES

5.1. Introduction

5.2. Abbott Laboratories

5.3. Biogen Idec

5.4. AstraZeneca

5.5. Bristol-Myers Squibb

5.6. Centocor Ortho Biotech

5.7. Centocor Ortho Biotech and Schering-Plough

5.8. Diamyd Medical

5.9. Eli Lilly and BioMS Medical

5.10. Eli Lilly and MacroGenics

5.11. Genzyme and Bayer

5.12. GlaxoSmithKline and Genmab

5.13. GlaxoSmithKline and Human Genome Sciences

5.14. GlaxoSmithKline and Tolerx

5.15. GlaxoSmithKline (Selected Additional Product Candidates and Research)

5.16. Isotechnika

5.17. Merck Serono and ZymoGenetics

5.18. Merck Serono

5.19. Novartis

Multiple Sclerosis

Rheumatoid Arthritis

Psoriasis

5.20. Pfizer

5.21. Roche and Chugai Pharmaceutical

5.22. Roche and Genentech (A Wholly-Owned Member of the Roche Group)

5.23. Sanofi-Aventis

5.24. Takeda Pharmaceutical and Millennium Pharmaceuticals

5.25. Teva Pharmaceutical Industries and Active Biotech

5.26. UCB

CHAPTER 6: EMERGING THERAPIES FOR TREATMENT OF ASTHMA

6.1. Pipeline Overview

6.2. Abbott Laboratories and SkyePharma (Also Mundipharma and Kyorin)

6.3. Aerovance

6.4. Amgen

6.5. AstraZeneca

6.6. Ception Therapeutics

6.7. Genentech

6.8. GlaxoSmithKline

6.9. Icagen

6.10. MediciNova

6.11. Pfizer

6.12. Schering-Plough and Novartis

6.13. Topigen Pharmaceuticals

6.14. Wyeth

CHAPTER 7: SELECTED EXAMPLES OF EMERGING THERAPIES FOR TREATMENT OF ALLERGIES

7.1. Introduction

7.2. ALK-Abello and Schering-Plough

7.3. Allergy Therapeutics

7.4. Ception Therapeutics

7.5. Cytos Biotechnology

7.6. Greer Laboratories

7.7. Stallergenes

CHAPTER 8: IMMUNOTHERAPIES IN DEVELOPMENT FOR PREVENTING REJECTION OF ORGAN TRANSPLANTS

8.1. Introduction

8.2. APT Pharmaceuticals

8.3. Astellas Pharma

8.4. Bristol-Myers Squibb

8.5. Isotechnika

8.6. Novartis

8.7. Pfizer

CHAPTER 9: BUSINESS CONSIDERATIONS --THERAPIES THAT SUPPRESS OR BALANCE THE IMMUNE SYSTEM

9.1. Current Market and Market Potential

9.2. Competition

9.3. Strong Interest on the Part of Major Pharmaceutical Companies

9.4. Agreements and Mergers/Acquisitions

9.5. Other Major Challenges and Hurdles Being Faced by Companies

Competition

Potential Need for Personalized Medicine in at Least Certain Situations

Targeted Patient Populations

CHAPTER 10: THOUGHT LEADER INTERVIEWS

10.1. David W. Pritchard, President and Chief Executive Officer, KaloBios

10.2. Randall C. Schatzman, PhD, President and Chief Executive Officer, Alder

Biopharmaceuticals

10.3. Louis Vaickus, MD, Chief Medical

Officer, Tolerx

10.4. Eric H. Zanelli, PhD, Vice President, Research, Peptimmune

REFERENCES

COMPANY INDEX WITH WEB ADDRESSES

To order this report:

Therapy Industry: Multiplex Assays: Evolving Technologies, Applications and Future Directions

More Market Research Report



    Contact:
    Nicolas Bombourg
    Reportlinker
    Email: nbo@reportlinker.com
    US: (805)652-2626
    Intl: +1 805-652-2626


SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com